Prostaglandin Analogs Market Size to Hit USD 6.38 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Prostaglandin Analogs Market

5.1. COVID-19 Landscape: Prostaglandin Analogs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Prostaglandin Analogs Market, By Product Type

8.1. Prostaglandin Analogs Market Revenue and Volume Forecast, by Product Type

8.1.1. Latanoprost

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Bimatoprost

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Travoprost

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Tafluprost

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Unoprostone

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Others (including new analogs and fixed-dose combinations)

8.1.6.1. Market Revenue and Volume Forecast

Chapter 9. Global Prostaglandin Analogs Market, By Formulation

9.1. Prostaglandin Analogs Market Revenue and Volume Forecast, by Formulation

9.1.1. Eye Drops

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Ophthalmic Solutions & Suspensions

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Injectables & Others

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Prostaglandin Analogs Market, By Indication

10.1. Prostaglandin Analogs Market Revenue and Volume Forecast, by Indication

10.1.1. Glaucoma and Ocular Hypertension

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Pulmonary Arterial Hypertension (PAH)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Labor Induction

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Prostaglandin Analogs Market, By Distribution Channel

11.1. Prostaglandin Analogs Market Revenue and Volume Forecast, by Distribution Channel

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Prostaglandin Analogs Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Product Type

12.1.2. Market Revenue and Volume Forecast, by Formulation

12.1.3. Market Revenue and Volume Forecast, by Indication

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Product Type

12.1.5.2. Market Revenue and Volume Forecast, by Formulation

12.1.5.3. Market Revenue and Volume Forecast, by Indication

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Product Type

12.1.6.2. Market Revenue and Volume Forecast, by Formulation

12.1.6.3. Market Revenue and Volume Forecast, by Indication

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Product Type

12.2.2. Market Revenue and Volume Forecast, by Formulation

12.2.3. Market Revenue and Volume Forecast, by Indication

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Product Type

12.2.5.2. Market Revenue and Volume Forecast, by Formulation

12.2.5.3. Market Revenue and Volume Forecast, by Indication

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Product Type

12.2.6.2. Market Revenue and Volume Forecast, by Formulation

12.2.6.3. Market Revenue and Volume Forecast, by Indication

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Product Type

12.2.7.2. Market Revenue and Volume Forecast, by Formulation

12.2.7.3. Market Revenue and Volume Forecast, by Indication

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Product Type

12.2.8.2. Market Revenue and Volume Forecast, by Formulation

12.2.8.3. Market Revenue and Volume Forecast, by Indication

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Product Type

12.3.2. Market Revenue and Volume Forecast, by Formulation

12.3.3. Market Revenue and Volume Forecast, by Indication

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Product Type

12.3.5.2. Market Revenue and Volume Forecast, by Formulation

12.3.5.3. Market Revenue and Volume Forecast, by Indication

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Product Type

12.3.6.2. Market Revenue and Volume Forecast, by Formulation

12.3.6.3. Market Revenue and Volume Forecast, by Indication

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Product Type

12.3.7.2. Market Revenue and Volume Forecast, by Formulation

12.3.7.3. Market Revenue and Volume Forecast, by Indication

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Product Type

12.3.8.2. Market Revenue and Volume Forecast, by Formulation

12.3.8.3. Market Revenue and Volume Forecast, by Indication

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Product Type

12.4.2. Market Revenue and Volume Forecast, by Formulation

12.4.3. Market Revenue and Volume Forecast, by Indication

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Product Type

12.4.5.2. Market Revenue and Volume Forecast, by Formulation

12.4.5.3. Market Revenue and Volume Forecast, by Indication

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Product Type

12.4.6.2. Market Revenue and Volume Forecast, by Formulation

12.4.6.3. Market Revenue and Volume Forecast, by Indication

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Product Type

12.4.7.2. Market Revenue and Volume Forecast, by Formulation

12.4.7.3. Market Revenue and Volume Forecast, by Indication

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Product Type

12.4.8.2. Market Revenue and Volume Forecast, by Formulation

12.4.8.3. Market Revenue and Volume Forecast, by Indication

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Product Type

12.5.2. Market Revenue and Volume Forecast, by Formulation

12.5.3. Market Revenue and Volume Forecast, by Indication

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Product Type

12.5.5.2. Market Revenue and Volume Forecast, by Formulation

12.5.5.3. Market Revenue and Volume Forecast, by Indication

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Product Type

12.5.6.2. Market Revenue and Volume Forecast, by Formulation

12.5.6.3. Market Revenue and Volume Forecast, by Indication

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Alcon (Novartis division)

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerProduct Typeance

13.1.4. Recent Initiatives

13.2. Allergan (AbbVie) (Lumigan - Bimatoprost)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerProduct Typeance

13.2.4. Recent Initiatives

13.3. Bausch + Lomb (part of Bausch Health)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerProduct Typeance

13.3.4. Recent Initiatives

13.4. Bausch Health Companies Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerProduct Typeance

13.4.4. Recent Initiatives

13.5. Chengdu Kanghong Pharmaceutical Group Co., Ltd.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerProduct Typeance

13.5.4. Recent Initiatives

13.6. Dr. Reddy’s Laboratories Ltd.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerProduct Typeance

13.6.4. Recent Initiatives

13.7. Eagle Pharmaceuticals, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerProduct Typeance

13.7.4. Recent Initiatives

13.8. Fresenius Kabi AG

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerProduct Typeance

13.8.4. Recent Initiatives

13.9. Glenmark Pharmaceuticals Ltd.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerProduct Typeance

13.9.4. Recent Initiatives

13.10. Hugel, Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerProduct Typeance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The prostaglandin analogs market size is expected to increase from USD 3.54 billion in 2024 to USD 6.38 billion by 2034.

The prostaglandin analogs market is expected to grow at a compound annual growth rate (CAGR) of around 6.06% from 2025 to 2034.

The major players in the prostaglandin analogs market include Alcon (Novartis division), Allergan (AbbVie) (Lumigan - Bimatoprost), Bausch + Lomb (part of Bausch Health), Bausch Health Companies Inc., Chengdu Kanghong Pharmaceutical Group Co., Ltd., Dr. Reddy’s Laboratories Ltd., Eagle Pharmaceuticals, Inc., Fresenius Kabi AG, Glenmark Pharmaceuticals Ltd., Hugel, Inc., Ipsen, Macleods Pharmaceuticals Ltd., Mylan N.V. (Viatris), Novartis AG, Pfizer Inc. (Xalatan - Latanoprost), Santen Pharmaceutical Co., Ltd., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., and Zhejiang Xianju Pharmaceutical Co., Ltd.

The driving factors of the prostaglandin analogs market are the rising glaucoma prevalence and increasing adoption of early treatment protocols supported by global health initiatives.

North America region will lead the global prostaglandin analogs market during the forecast period 2025 to 2034.